Post-operative adjuvant chemotherapy for colorectal cancer with 5-fluorouracil (5-FU) infusion combined with 1-hexylcarbamoyl-5-fluorouracil (HCFU) oral administration after curative resection

Anticancer Research

Volumn 21, Issue 6 A, 2001, Pages 4163-4168

  Iwagaki, Hiromi ^a   Tanaka, Noriaki ^a   Esato, Kensuke ^a   Kaibara, Nobuaki ^a   Sano, Kaiso ^a   Dohi, Kiyohiko ^a   Toge, Tetsuya ^a   Nakamura, Teruhisa ^a   Nakasato, Hiroaki ^a   Orita, Kunzo ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

5 iluorouracil and 1 hexylcarbamoyl 5 fluorouracil; Adjuvant chemotherapy; Colorectal cancer

Indexed keywords

CARMOFUR; FLUOROURACIL;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION; DRUG MEGADOSE; FEMALE; HOT FLUSH; HUMAN; LEUKOPENIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PARESTHESIA; POLLAKISURIA; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; VERTIGO;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES;

EID: 0035569262     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Pattern of recurrence following curative resection of adenocarcinoma of the colon and rectum
2. Patterns of recurrence of rectal cancer after potentially curative surgery
3. Prognostic factors for patients with colon or rectal carcinoma treated with resection only: Five-year follow-up report
4. Antitumor activity of carbamoyl derivatives of 5-fluorouracil by oral administration
5. Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in a variety of experimental tumors
6. Antitumor activity of metalbolites of 1-hexylcarbamoyl-5-fluorouracil and related compounds against L1210 leukemia in vivo and L5178Y lymphoma cells in vitro
7. Absorption and excretion of a new oral antitumor drug, 1-hexylcarbamoyl-5-fluorouracil (HCFU), in cancer patients
8. Metabolic fate of 1-hexylcarbamoyl-5-fluorouracil in rats
9. Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumors
10. Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in Lewis lung carcinoma and B16 melanoma
11. Enhancement of antitumor effects of 1-hexylcarbamoyl-5-fluorouracil compnecl with hyperthermia on Ehrlich ascites tumor in vivo and Nakahara-Fukuoka sarcoma cell in vivo
12. Sensitivity test for 5-fluorouracil ancl its analogues. 1-2-tetrahydrofuryl)-5-fluorouracil, uracil/1-(2-tetrahydrofuryl)-5-fluorouracil (4:1) and 1-hexylcarbamoyl-5-fluorouracil, using the subrenal capsule assay
13. Modulation by 1-leucovorin of 1-hexylcarbamoyl-5-fluorouracil antitumor activity on humam gastric and colon carcinoma serially transplantecl into nude mice
14. Chemotherapy of large bowel cancer
15. An analysis of chemotherapy for colorectal carcinoma
16. 1-Hexylcarbamoyl-5-fluorouracil (HCFU) - A masked fluorinated pyrimidine
17. Randomized controlled trial of 5-fluorouracil (5-FU) infusion combined wilh 1-hexylcarbamoyl-5-tluorouracil (HCFU) oral administration and HCFU alone as postoperative acljuvant chemotherapy for colorectal cancer
18. Sequential treatment assignment with balancing prognostic factors in the controlled clinical trial
19. The randomization and stratification of patients to clinical trials
20. Postoperative chemotherapy for colorectal cancer by coming 5-fluorouracil administration after curative resection